Decoy FGFR3 protein appears to prevent dwarfism in mice

September 24, 2013 by Bob Yirka, Medical Xpress report

X-ray radiographs illustrating treatment effect on skeletal growth. Credit: Sci. Transl. Med. 5, 203ra124 (2013) DOI: 10.1126/scitranslmed.3006247
(Medical Xpress)—A team made up of researchers from several institutions in France has found that a decoy protein injected into mice, appears to prevent the development of dwarfism. In their paper published in the journal Science, the team describes how they used a recombinant protein therapeutic approach with a soluble form of a human protein to counteract the gene mutation responsible for dwarfism in mice.

Dwarfism is a condition where people have short arms and legs relative to their torso and head. In addition to causing , it has been found to cause spinal and breathing problems. Currently, there is no cure for the condition. In this new effort, the researchers in France are reporting that they've made major headway in preventing it from happening—at least in mice.

Prior research has revealed that most types of dwarfism are caused by a mutation in the FGFR3 gene—it leads to receptors on the surface of chondrocytes () becoming hyperactive, preventing the proper formation of bone. To prevent the chondrocytes from becoming hyperactive, the researchers developed a soluble form of a protein to act as a decoy—they called it sFGFR3—it bonds with growth factors in instead of with those generated by the mutant FGFR3 gene protein.

The result, the team reports is the prevention of dwarfism in test mice (that had a condition similar to achondroplasia—the most common form of dwarfism in humans) that were injected with the protein twice a week for three weeks. They report also that other problems associated with dwarfism disappeared as well and that the treated mice gave birth to normal mice after reaching adulthood, showing that the skeletal structures of the mice were sufficient for delivery.

So optimistic are the researchers about their results, they are predicting that their protein will be ready for clinical trials very soon and that the protein could conceivably be ready for delivery to patients as soon as three to five years from now—effectively eradicating in the future. They point out that the therapy will only work when given to children (pre-puberty) most likely, shortly after birth.

Explore further: Research team identifies gene mutation that causes loss of pain perception

More information: S. Garcia, B. Dirat, T. Tognacci, N. Rochet, X. Mouska, S. Bonnafous, S. Patouraux, A. Tran, P. Gual, Y. L. Marchand-Brustel, I. Gennero, E. Gouze, Postnatal Soluble FGFR3 Therapy Rescues Achondroplasia Symptoms and Restores Bone Growth in Mice. Sci. Transl. Med. 5, 203ra124 (2013) DOI: 10.1126/scitranslmed.3006247

Abstract
Achondroplasia is a rare genetic disease characterized by abnormal bone development, resulting in short stature. It is caused by a single point mutation in the gene coding for fibroblast growth factor receptor 3 (FGFR3), which leads to prolonged activation upon ligand binding. To prevent excessive intracellular signaling and rescue the symptoms of achondroplasia, we have developed a recombinant protein therapeutic approach using a soluble form of human FGFR3 (sFGFR3), which acts as a decoy receptor and prevents FGF from binding to mutant FGFR3. sFGFR3 was injected subcutaneously to newborn Fgfr3ach/+ mice—the mouse model of achondroplasia—twice per week throughout the growth period during 3 weeks. Effective maturation of growth plate chondrocytes was restored in bones of treated mice, with a dose-dependent enhancement of skeletal growth in Fgfr3ach/+ mice. This resulted in normal stature and a significant decrease in mortality and associated complications, without any evidence of toxicity. These results describe a new approach for restoring bone growth and suggest that sFGFR3 could be a potential therapy for children with achondroplasia and related disorders.

Related Stories

Research team identifies gene mutation that causes loss of pain perception

September 16, 2013
(Medical Xpress)—A large team of European researchers has identified a gene mutation that is responsible for causing a condition that leads to an inability to experience pain in humans. In their paper published in Nature ...

Researchers erase human brain tumor cells in mice

September 23, 2013
Working with mice, Johns Hopkins researchers have discovered that weeks of treatment with a repurposed FDA-approved drug halted the growth of—and ultimately left no detectable trace of—brain tumor cells taken from adult ...

Key regulator of blood vessel formation could be a potential new target for cancer drugs

August 30, 2013
During formation of the vascular system, successively smaller blood vessels sprout from existing ones to form networks of capillaries in patterns uniquely adapted to the function of the organ they enter. This process, called ...

Autism gene stunts neurons, but growth can be restored, in mice

September 12, 2013
Brown University researchers have traced a genetic deficiency implicated in autism in humans to specific molecular and cellular consequences that cause clear deficits in mice in how well neurons can grow the intricate branches ...

Recommended for you

Exercise-induced hormone irisin triggers bone remodeling in mice

December 13, 2018
Exercise has been touted to build bone mass, but exactly how it actually accomplishes this is a matter of debate. Now, researchers show that an exercise-induced hormone activates cells that are critical for bone remodeling ...

Law professor suggests a way to validate and integrate deep learning medical systems

December 13, 2018
University of Michigan professor W. Nicholson Price, who also has affiliations with Harvard Law School and the University of Copenhagen Faculty of Law, suggests in a Focus piece published in Science Translational Medicine, ...

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

Pain: Perception and motor impulses arise in brain independently of one another

December 13, 2018
Pain is a negative sensation that we want to get rid of as soon as possible. In order to protect our bodies, we react by withdrawing the hand from heat, for example. This action is usually understood as the consequence of ...

Drug targets for Ebola, Dengue, and Zika viruses found in lab study

December 13, 2018
No drugs are currently available to treat Ebola, Dengue, or Zika viruses, which infect millions of people every year and result in severe illness, birth defects, and even death. New research from the Gladstone Institutes ...

Researchers give new insight to muscular dystrophy patients

December 13, 2018
New research by University of Minnesota scientists has revealed the three-dimensional structure of the DUX4 protein, which is responsible for the disease, facioscapulohumeral muscular dystrophy (FSHD). Unlike the majority ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.